Nilotinib – Key patent, SPC, and data exclusivity expiry (44 country coverage):Life Sciences Market Research Reports

Life Sciences Market Research Reports

Nilotinib – Key patent, SPC, and data exclusivity expiry (44 country coverage) Jun 6th 2013, 00:00 Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Nilotinib Nilotinib indications: Treatment of Philadelphia chromosome positive chronic myeloid leukaemia, optionally in combination with erythropoietin, G-CSF, hydroxyurea or Anagrelide Nilotinib innovator: Novartis (Tasigna) Examples of information found in this online report include: # Includes key patent publications for 44 countries (see list below) # Contains SPC protection for every EU state plus … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=99819. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/nilotinib-key-patent-spc-and-data-exclusivity-expiry-44-country-coverage-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions